PDCD1 and melanoma: Indeed, Tsuruta et al. [25] showed that circadian PD-1 expression on TAMs impacts the anti-tumor effect of the PD-1/PD-L1 inhibitor BMS-1 in melanoma-bearing mice, with tumor growth significantly suppressed by the administration of BMS-1 during the night.